CureLab
- Biotech or pharma, therapeutic R&D
- Biotech or pharma, animal health
Clinical stage company Main asset: anticancer immunotherapy DNA. In Phase I/II human trials conducted ex-US, Elenagen demonstrated a statistically significant extension of progression-free (PFS) and overall (OS) survival for stage III/IV cancer patients. The primary goal is to repeat and extend the ex-US clinical trials as FDA/EMA phase II trials in the USA/EU and/or out-licensing. Repeating and extending a statistically significant success in the USA/EU is a low-risk, high-reward proposition.
Alternative markets:
- Human diseases of chronic inflammation
- Veterinary medicine
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}